P2RY12 and cancer: The comparable stent healing visualized by OCT between cancer and non-cancer patients regardless of stent brand and the P2Y12 inhibitor discontinuation not impacting survival should encourage a personalized approach to stent healing management that accounts for cancer status and prognosis.